CTRI/2017/02/007912已完成3 期
A Multi-center, Randomized, Double-blind, Placebocontrolled Trial to Evaluate the Effects of IntraErythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - ATTeST
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- EryDel SpA
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patient meets clinical criteria for diagnosis of AT. The neurological signs of AT (in coordination of the head and eyes in lateral gaze deflection, gait ataxia associated with an inappropriately narrow base) must be documented.
- •2.Patient is in autonomous gait or is helped by periodic use of a support.
- •3.Patient will be investigated for the proven genetic diagnosis of AT (prior documentation or by central laboratory test report).
- •4.Patient is at least 6 years of age, of either sex.
- •5.Body weight > 15 kg. 6. The patient and his/her parent/caregiver (if below the age of consent), or a legal representative, has provided written informed consent to participate. If consent is provided solely by the caregiver in accordance with local regulations, the patient must provide assent to participate in the study.
排除标准
- •1.Females that are of childbearing potential, pregnant, or are breast-feeding. Females of childbearing potential using adequate birth control, as determined by their Health Care Provider, will be eligible.
- •2. A disability that may prevent the patient from completing all study requirements.
- •3.Current participation in another clinical study.
- •Medical History and Current Status
- •4.CD4+ lymphocytes count <400/mm3 (for patients 6 years of age) or <200/mm3 (for patients >6 years).
- •5.Loss/removal of 250 mL or more of blood within the past 4 weeks prior to screening.
- •6.Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years.
- •7.History of severe impairment of the immunological system.
- •8.Severe or unstable pulmonary disease.
- •9.Uncontrolled diabetes. Patients with diabetes that has been stabilized (i.e. no hypoglycemic or hyperglycemic episodes in the past 3 months) will be eligible.
- •10.Any other severe, unstable, or serious disease or condition that in the Investigatorââ?¬•s opinion would put the patient at risk for imminent lifethreatening morbidity, need for hospitalization, or mortality.
- •11.Any clinically significant abnormality on standard laboratory examinations (hematology, biochemistry, urinalysis) at screening that remains abnormal on repeat testing. Eligibility of patients with abnormal laboratory test values will be determined by the Investigator in consultation with the Medical Monitor.
- •12.Confirmed hemoglobinopathies, e.g. hemoglobin C disease, sickle cell anemia, or thalassemia.
- •13.Moderate or severe renal and/or hepatic impairment. Prior/Concomitant Medication.
- •14.Any previous oral or parenteral steroid use within 4 weeks before Baseline. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted.
- •15.Chronic condition or prior allergic reaction representing a contraindication to the use of dexamethasone or other steroid drugs.
- •16.Has participated in any other trial with an investigational drug and received a dose within 30 days or 10 half-lives (whichever is greater) from the start of the 30-day Screening Period.
- •17.Has participated in a previous trial with EDS.
- •18.Requires any concomitant medication prohibited by the protocol.
- •19.Has taken a drug or treatment known to cause major organ system toxicity during the past year.
- •20.Use of any drug that is a strong inducer/inhibitor of CYP3A4 within 4 weeks before baseline.
研究者
相似试验
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo - controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing - M10-261, FINAL 30Nov07MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-005905-23-GBAbbott GmbH & Co. KG424
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo - controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week DosingRheumatoid ArthritisEUCTR2007-005905-23-DEAbbott GmbH & Co. KG424
暂停
3 期
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- AntihistaminesChronic Inducible UrticariaCINDUCINDLBCTR2022014919ovartis Pharmaceuticals8
已完成
2 期
A Dose response study in patients with mild to moderate hypertension.CTRI/2011/04/001682ovartis Healthcare Pvt Ltd910
进行中（未招募）
1 期
To assess the efficacy of NTRA-2112 on intestinal malabsorption due to gastro-intestinal immaturity by measuring the time required to reach full enteral feeding in preterm infants during the treatment period compared to a placebo formulation.Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants.MedDRA version: 20.1Level: LLTClassification code 10025479Term: Malabsorption syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: PTClassification code 10025476Term: MalabsorptionSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.0Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-002624-28-FRutrinia300